Astec Lifesciences (NSE:ASTEC) Operating Income: ₹-494 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:ASTEC Astec Lifesciences Ltd NSE:ASTEC
76 GF Score
Price ₹690.75
GF Value ₹993.59
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Astec Lifesciences Operating Income?

Astec Lifesciences NSE:ASTEC -1.38% 76 Operating Income is ₹-494 Mil as of Mar. 2026. GuruFocus rates NSE:ASTEC with a GF Score™ of 76/100 and a GF Value™ of ₹993.59 (Significantly Undervalued). The stock has 4 warning signs investors should review.

Astec Lifesciences's Operating Income for the three months ended in Mar. 2026 was ₹-26 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was ₹-494 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Astec Lifesciences's Operating Income for the three months ended in Mar. 2026 was ₹-26 Mil. Astec Lifesciences's Revenue for the three months ended in Mar. 2026 was ₹1,586 Mil. Therefore, Astec Lifesciences's Operating Margin % for the quarter that ended in Mar. 2026 was -1.65%.

Astec Lifesciences's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Astec Lifesciences's annualized ROC % for the quarter that ended in Mar. 2026 was -1.13%. Astec Lifesciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 0.01%.

Astec Lifesciences  (NSE:ASTEC) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Astec Lifesciences's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-104.46 * ( 1 - 1.94% )/( (0 + 9048.524)/ 1 )
=-102.433476/9048.524
=-1.13 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0 - 0 - ( 0 - max(0, 0 - 0+0))
=0

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=9420.382 - 939.811 - ( 105.361 - max(0, 4997.864 - 4429.911+105.361))
=9048.524

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Astec Lifesciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=0.884/( ( (0 + max(0, 0)) + (4548.122 + max(3290.022, 0)) )/ 1 )
=0.884/( ( 0 + 7838.144 )/ 1 )
=0.884/7838.144
=0.01 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0) - (0 + 0 + 0)
=0

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(2477.168 + 1380.332 + 441.087) - (939.811 + 0 + 68.754)
=3290.022

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Astec Lifesciences's Operating Margin % for the quarter that ended in Mar. 2026 is calculated as:

Operating Margin %=Operating Income (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-26.115/1586.226
=-1.65 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.

Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.

Astec Lifesciences Operating Income Related Terms

Astec Lifesciences Operating Income Historical Data

* Premium members only.

The historical data trend for Astec Lifesciences's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Astec Lifesciences Operating Income Chart

Astec Lifesciences Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,203.33 435.27 -415.94 -1,092.84 -493.82

Astec Lifesciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -60.52 -224.80 -171.26 -72.31 -26.12
NSE:ASTEC
76GF Score
Astec Lifesciences Ltd NSE:ASTEC
Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Astec Lifesciences Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-494 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Income →
What does a Operating Income of ₹-494 Mil mean?
Astec Lifesciences (NSE:ASTEC) has a Operating Income of ₹-494 Mil as of Mar. 2026. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on Astec Lifesciences and its competitors.
Is Astec Lifesciences' Operating Income too high?
Astec Lifesciences' current Operating Income is ₹-494 Mil. Overall, Astec Lifesciences has a GF Score™ of 76/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Astec Lifesciences' Operating Income compare to CTVA and CF?
Astec Lifesciences' Operating Income of ₹-494 Mil can be compared against companies in the Agriculture industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Income for an Agriculture company?
A good Operating Income depends on the Agriculture industry context. However, Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Income mean?
A high Operating Income can signal that a stock is expensive relative to its fundamentals. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on Astec Lifesciences and its competitors. Astec Lifesciences's current Operating Income is ₹-494 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Astec Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Astec Lifesciences (NSE:ASTEC) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹993.59, compared to a current price of ₹690.75 — trading 30.5% below its estimated fair value. The current Operating Income is ₹-494 Mil. Astec Lifesciences' overall GF Score™ is 76/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Income calculated?
Operating Income is calculated from a company's financial statements. For Astec Lifesciences (NSE:ASTEC), the current Operating Income is ₹-494 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Astec Lifesciences (NSE:ASTEC) Overvalued in 2026?

Based on GuruFocus' analysis, Astec Lifesciences stock appears to be undervalued. The current stock price of ₹690.75 is trading 30.5% below its estimated GF Value™ of ₹993.59. GuruFocus considers Astec Lifesciences to be Significantly Undervalued.

Key valuation signals for NSE:ASTEC:

  • Operating Income: ₹-494 Mil
  • GF Value™: ₹993.59 vs. price of ₹690.75 (30.5% below fair value)
  • GF Score™: 76/100 with 4 warning signs

No single metric tells the full story. See the NSE:ASTEC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Astec Lifesciences Business Description

Other Exchanges 533138:India
Address Eastern Express Highway, Godrej One, 3rd Floor, Pirojshanagar, Vikhroli (East), Mumbai, MH, IND, 400 079
Astec Lifesciences Ltd manufactures & distributes a wide range of Agrochemical active ingredients and pharmaceutical intermediates. The company's products include agrochemicals, such as Triazole Fungicides, Herbicides, and Insecticides. The company is also into Intermediates & Specialty chemicals. Geographically, all the operations of the firm function through India; however, its products are sold in the Indian and overseas markets. It operates in the business segment of Agrochemicals and has a business presence in India and outside India.
76GF Score

Get the complete analysis for NSE:ASTEC

Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹690.75
Price
₹993.59
GF Value